Literature DB >> 6386330

Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations.

R K Fuller, W O Williford, K K Lee, R Derman.   

Abstract

Disulfiram treatment of alcoholism has been difficult to evaluate in controlled studies because the study design must contend with problems unique to this drug. The therapeutic effect may be a result of the patient's fear of the disulfiram-ethanol reaction rather than a direct pharmacological effect on the craving for alcohol. Good outcome may not be directly related to compliance with the drug regimen; a patient may remain abstinent even if he does not take his medication. The Veterans Administration Cooperative Study "Disulfiram in the Treatment of Alcoholism," is a multicenter, randomized, blinded, controlled clinical trial designed to evaluate the efficacy of disulfiram while addressing these issues. Two control groups are used. The members of one control group will not receive disulfiram and will be told they are not receiving disulfiram. The members of the other control group will be given disulfiram and will be told they are receiving disulfiram; however, the dose of their disulfiram will be measured by doing pill counts and obtaining urine specimens at each clinic visit and measuring urinary diethylamine, a metabolite of disulfiram, and riboflavin (a medication marker).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386330     DOI: 10.1016/0197-2456(84)90030-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  3 in total

1.  A causal model for joint evaluation of placebo and treatment-specific effects in clinical trials.

Authors:  Zhiwei Zhang; Richard M Kotz; Chenguang Wang; Shiling Ruan; Martin Ho
Journal:  Biometrics       Date:  2013-02-22       Impact factor: 2.571

2.  Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial.

Authors:  V-M S Ramanujam; Fatima Nayeem; Karl E Anderson; Yong-Fang Kuo; Nai-Wei Chen; Hyunsu Ju; Lee-Jane W Lu
Journal:  Biomarkers       Date:  2016-12-23       Impact factor: 2.658

3.  Joint Estimation of Treatment and Placebo Effects in Clinical Trials with Longitudinal Blinding Assessments.

Authors:  Wei Liu; Zhiwei Zhang; R Jason Schroeder; Martin Ho; Bo Zhang; Cynthia Long; Hui Zhang; Telba Z Irony
Journal:  J Am Stat Assoc       Date:  2016-08-18       Impact factor: 5.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.